source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Outset Medical issues safety alert for Tablo dialysis system power cords overheat riskThe FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…